ArticleBMC public health2025
Social capital and its association with clinically significant depressive symptoms in patients with end-stage kidney disease in Mexico.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPatients with end-stage kidney disease (ESKD) undergoing renal replacement therapy often face significant psychological distress and depression. The social environment of these individuals may influence depressive symptoms, but research on social capital in this group is limited. This study aimed to assess the prevalence of clinically significant depressive symptoms and explore the association between different dimensions of social capital and clinically significant depressive symptoms in ESKD patients.
methodsA cross-sectional study was conducted involving 819 patients with ESKD who were undergoing peritoneal dialysis or hemodialysis at three medical facilities of the Mexican Institute of Social Security in Aguascalientes, Mexico. Data on patients’ characteristics was collected from April 2023 to January 2024. Depressive symptoms were measured on the Beck Depression Inventory II, considering a score of 17 or higher as indicative of clinically significant depressive symptoms. We utilized a validated Social Capital Questionnaire specifically designed for ESKD patients in Mexico to evaluate structural and cognitive social capital and its dimensions. Multivariable logistic regression analysis was performed to evaluate the association between social capital and clinically significant depressive symptoms.
resultsThe prevalence of clinically significant depressive symptoms was 27.2% (95% CI 0.24–0.30). In the structural domain of social capital, “network size” (OR 0.85; 95% CI 0.80–0.91) and “bonding within social groups” (OR 0.85; 95% CI 0.78–0.93) were associated with lower odds of clinically significant depressive symptoms, while “vertical bridging” was associated with higher odds (OR 1.06; 95% CI 1.02–1.10). In the cognitive domain, “norms of reciprocity” (OR 0.97; 95% CI 0.95–0.99), “sense of belonging” (OR 0.92; 95% CI 0.87–0.96), and “social support” (OR 0.85; 95% CI 0.80–0.90) were associated with decreased odds of clinically significant depressive symptoms, while “sense of fairness” was associated with increased odds.
conclusionMost social capital dimensions are associated with decreased odds of clinically significant depressive symptoms in patients with ESKD. Our findings emphasize the need for strategies that enhance the protective aspects of social capital, ultimately helping to reduce the prevalence of depressive symptoms among patients with ESKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.